Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression.

Lilly Y W Bourguignon, Marisa Shiina, Jian-Jian Li
Author Information
  1. Lilly Y W Bourguignon: Department of Medicine, University of California at San Francisco & Endocrine Unit (111N), VA Medical Center, San Francisco, California, USA. Electronic address: lilly.bourguignon@ucsf.edu.
  2. Marisa Shiina: Department of Medicine, University of California at San Francisco & Endocrine Unit (111N), VA Medical Center, San Francisco, California, USA.
  3. Jian-Jian Li: Department of Radiation Oncology, University of California Davis, Sacramento, California, USA.

Abstract

Hyaluronan (HA), a major component of the extracellular matrix (ECM), is enriched in many types of tumors. There is good evidence linking high levels of HA production in human carcinomas to an aggressive phenotype and tumor metastasis. HA is generally bound to CD44 isoforms (so-called CD44s and CD44v3) which are ubiquitous, abundant, and functionally important cell surface receptors. This chapter describes the evidence for HA/CD44v3-mediated activation of the cytoskeleton (e.g., ankyrin and GTPases) and matrix metalloproteinase (MMP) signaling during tumor progression. A special focus is placed on the role of HA-CD44v3 interaction in cancer stem cells (CSCs). Matrix HA is known to be present in CSC niches. Since CD44v3 serves as a CSC marker, it provides an important physical linkage between matrix HA and various transcription factors that regulate tumor cell functions through distinct signaling pathways. CSCs are known to be chemoresistant and/or radiation resistant and to cause cancer relapse. The purpose of this chapter is to review the most current research on the cellular and molecular biology of CSCs. The emphasis will be placed on both CSC niche and matrix HA-induced microRNA signaling plus various CSC functions (e.g., self-renewal, differentiation, and chemoresistance) during cancer progression. Understanding the regulation of CSCs is critically important for designing CSC-specific therapeutic targets to prevent cancer development and progression.

Keywords

References

  1. J Biol Chem. 1996 Apr 26;271(17):9875-8 [PMID: 8626618]
  2. Biochem J. 1998 Mar 15;330 ( Pt 3):1223-7 [PMID: 9494089]
  3. J Biol Chem. 2008 Jun 20;283(25):17635-51 [PMID: 18441325]
  4. J Biol Chem. 2003 Jul 11;278(28):25285-8 [PMID: 12738783]
  5. J Cell Biol. 1994 Aug;126(4):1099-109 [PMID: 7519619]
  6. Annu Rev Cell Biol. 1992;8:67-113 [PMID: 1282354]
  7. J Biol Chem. 2002 Oct 18;277(42):39703-12 [PMID: 12145287]
  8. J Cell Physiol. 1998 Jul;176(1):206-15 [PMID: 9618160]
  9. Head Neck. 2000 Dec;22(8):748-59 [PMID: 11084634]
  10. Stem Cells Dev. 2009 Sep;18(7):1093-108 [PMID: 19480567]
  11. Cytogenet Genome Res. 2004;105(2-4):442-7 [PMID: 15237232]
  12. Regen Med. 2006 Jul;1(4):437-45 [PMID: 17465836]
  13. Oncogene. 2003 Dec 8;22(56):9075-86 [PMID: 14663486]
  14. FASEB J. 1992 Apr;6(7):2397-404 [PMID: 1563592]
  15. Breast Cancer Res. 2006;8(5):R59 [PMID: 17062128]
  16. Am J Pathol. 2011 Mar;178(3):956-63 [PMID: 21356346]
  17. Head Neck. 2003 Aug;25(8):654-61 [PMID: 12884349]
  18. J Biol Chem. 2001 Dec 28;276(52):48679-92 [PMID: 11606575]
  19. Science. 1987 Jan 9;235(4785):177-82 [PMID: 3798106]
  20. Biochem Pharmacol. 1999 Apr 1;57(7):727-41 [PMID: 10075079]
  21. J Biol Chem. 2001 Mar 9;276(10):7327-36 [PMID: 11084024]
  22. Cell Motil Cytoskeleton. 1998;39(3):209-22 [PMID: 9519902]
  23. Curr Opin Cell Biol. 2000 Oct;12(5):581-6 [PMID: 10978893]
  24. Laryngoscope. 2009 Aug;119(8):1518-30 [PMID: 19507218]
  25. J Clin Oncol. 1986 Jun;4(6):952-7 [PMID: 3519884]
  26. Cell. 2005 Sep 23;122(6):947-56 [PMID: 16153702]
  27. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [PMID: 12629218]
  28. Head Neck. 2007 Jun;29(6):550-8 [PMID: 17252589]
  29. Cell. 1991 Apr 5;65(1):13-24 [PMID: 1707342]
  30. Am J Pathol. 2002 Sep;161(3):745-7 [PMID: 12213700]
  31. Apoptosis. 2007 Sep;12(9):1543-68 [PMID: 17573556]
  32. Histopathology. 2005 Oct;47(4):420-8 [PMID: 16178897]
  33. J Biol Chem. 2002 Feb 15;277(7):4589-92 [PMID: 11717317]
  34. J Biol Chem. 2004 Jun 25;279(26):26991-7007 [PMID: 15090545]
  35. Nat Med. 1997 Jul;3(7):730-7 [PMID: 9212098]
  36. J Cell Sci. 1992 Oct;103 ( Pt 2):293-8 [PMID: 1282514]
  37. J Biol Chem. 2000 Jan 21;275(3):1829-38 [PMID: 10636882]
  38. J Biol Chem. 1997 Oct 31;272(44):27913-8 [PMID: 9346940]
  39. Head Neck. 2000 Sep;22(6):599-608 [PMID: 10941162]
  40. Oncogene. 2008 Apr 3;27(15):2128-36 [PMID: 17968323]
  41. Oncogene. 2004 Jan 15;23(2):535-45 [PMID: 14724581]
  42. Biochem Soc Trans. 1999 Feb;27(2):109-15 [PMID: 10093717]
  43. Br J Cancer. 1998;77(1):147-52 [PMID: 9459160]
  44. Cancer Biol Ther. 2004 Sep;3(9):819-24 [PMID: 15326379]
  45. J Biol Chem. 1996 May 3;271(18):10672-80 [PMID: 8631874]
  46. Front Biosci. 1998 Jul 01;3:d637-49 [PMID: 9634539]
  47. Physiol Rev. 2001 Jul;81(3):1353-92 [PMID: 11427698]
  48. Science. 1998 Jan 23;279(5350):509-14 [PMID: 9438836]
  49. Nature. 1990 Mar 1;344(6261):36-42 [PMID: 2137557]
  50. Oncogene. 2012 Jan 12;31(2):149-60 [PMID: 21685938]
  51. Front Biosci (Landmark Ed). 2011 Jan 01;16:261-76 [PMID: 21196170]
  52. Cell Motil Cytoskeleton. 1999;43(4):269-87 [PMID: 10423269]
  53. Otolaryngol Head Neck Surg. 2001 Apr;124(4):426-32 [PMID: 11283501]
  54. Clin Cancer Res. 2012 Dec 15;18(24):6634-47 [PMID: 23091114]
  55. Cell. 1996 May 31;85(5):683-93 [PMID: 8646777]
  56. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160-4 [PMID: 1465456]
  57. Mol Biol Rep. 2011 Mar;38(3):2155-60 [PMID: 20857206]
  58. Enzyme Protein. 1996;49(1-3):59-71 [PMID: 8796997]
  59. Semin Cell Dev Biol. 2001 Apr;12(2):79-87 [PMID: 11292373]
  60. Virchows Arch. 1996 Apr;428(1):29-35 [PMID: 8646366]
  61. Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):281-8 [PMID: 17372087]
  62. Oncol Res. 2003;13(6-10):323-31 [PMID: 12725521]
  63. J Biol Chem. 2003 Aug 8;278(32):29420-34 [PMID: 12748184]
  64. PLoS One. 2008;3(10):e3360 [PMID: 18852874]
  65. J Biol Chem. 2012 Sep 21;287(39):32800-24 [PMID: 22847005]
  66. J Biol Chem. 2009 Sep 25;284(39):26533-46 [PMID: 19633292]
  67. Int J Cancer. 1999 May 31;81(5):682-7 [PMID: 10328216]
  68. J Cell Physiol. 1997 May;171(2):152-60 [PMID: 9130462]
  69. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1730-4 [PMID: 1689849]
  70. Radiat Res. 2009 Jan;171(1):9-21 [PMID: 19138055]
  71. J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):287-97 [PMID: 11547898]
  72. J Biol Chem. 1997 May 30;272(22):13997-4000 [PMID: 9206724]
  73. Cancer Res. 2008 Nov 15;68(22):9384-93 [PMID: 19010913]
  74. J Biol Chem. 2006 May 19;281(20):14026-40 [PMID: 16565089]
  75. Semin Cancer Biol. 2008 Aug;18(4):251-9 [PMID: 18450475]
  76. Mol Cell Biol. 2008 Oct;28(20):6426-38 [PMID: 18710938]
  77. Cell. 2008 Jul 11;134(1):62-73 [PMID: 18614011]
  78. Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):771-8 [PMID: 16847188]
  79. J Biol Chem. 2007 Jan 12;282(2):1265-80 [PMID: 17092940]
  80. J Cell Physiol. 1995 Jan;162(1):127-33 [PMID: 7529235]

Grants

  1. I01 BX000628/BLRD VA
  2. I01 RX000601/RRD VA
  3. R01 CA066163/NCI NIH HHS
  4. R01 CA66163/NCI NIH HHS

MeSH Term

Animals
Ankyrins
Apoptosis
Cell Movement
Cell Proliferation
Cell Survival
Cytoskeleton
Disease Progression
Drug Resistance, Neoplasm
Humans
Hyaluronan Receptors
Hyaluronic Acid
Mice
MicroRNAs
Neoplasm Invasiveness
Neoplasms
Neoplastic Cells, Circulating
Neoplastic Stem Cells
Phenotype
Signal Transduction
rho GTP-Binding Proteins

Chemicals

Ankyrins
CD44 protein, human
Hyaluronan Receptors
MicroRNAs
Hyaluronic Acid
rho GTP-Binding Proteins

Word Cloud

Created with Highcharts 10.0.0HAprogressioncancermatrixtumorsignalingCSCsCSCimportantstemcellsfunctionsevidenceCD44CD44v3cellchapteregplacedinteractionMatrixknownvariousradiationmicroRNAchemoresistanceresistanceHyaluronanmajorcomponentextracellularECMenrichedmanytypestumorsgoodlinkinghighlevelsproductionhumancarcinomasaggressivephenotypemetastasisgenerallyboundisoformsso-calledCD44subiquitousabundantfunctionallysurfacereceptorsdescribesHA/CD44v3-mediatedactivationcytoskeletonankyrinGTPasesmetalloproteinaseMMPspecialfocusroleHA-CD44v3presentnichesSinceservesmarkerprovidesphysicallinkagetranscriptionfactorsregulatedistinctpathwayschemoresistantand/orresistantcauserelapsepurposereviewcurrentresearchcellularmolecularbiologyemphasiswillnicheHA-inducedplusself-renewaldifferentiationUnderstandingregulationcriticallydesigningCSC-specifictherapeutictargetspreventdevelopmentHyaluronan-CD44promotesoncogenicleadingCancerChemoresistancehyaluronanRadiationTumormicroRNAs

Similar Articles

Cited By